Company intelligence / Profile preview

PALA Pharmaceuticals

Cleveland, OH, USApalapharmaceutical.com ↗
Ownership
Private
Development stage
Other
01

Overview

PALA Pharmaceuticals is a biotechnology company focused on repurposing the small molecule PALA (N-phosphonacetyl-L-aspartate) for oncology and infectious diseases. Originally developed in the 1970s as a high-dose metabolic inhibitor, PALA has been rediscovered as a potent immune activator at low, safe doses. The company's lead programs utilize systemic and topical delivery methods to block the CAD protein, which in turn activates the NOD2 immune pathway to enhance the body's anti-tumor and antimicrobial responses.

Therapeutic areas
OncologyInfectious Diseases
Modalities
Small molecule
Industry
Biotech
02

Drug pipeline

1 asset

sparfosic acid

Discontinued
03

Partnerships

Cleveland Clinic

Beyond the preview

Go deeper on PALA Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PALA Pharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call